EFG Asset Management Americas Corp. Has $9.11 Million Position in Johnson & Johnson (NYSE:JNJ)

EFG Asset Management Americas Corp. reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 2.3% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 58,124 shares of the company’s stock after selling 1,388 shares during the quarter. Johnson & Johnson comprises about 2.0% of EFG Asset Management Americas Corp.’s portfolio, making the stock its 8th biggest position. EFG Asset Management Americas Corp.’s holdings in Johnson & Johnson were worth $9,110,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Moseley Investment Management Inc. increased its holdings in shares of Johnson & Johnson by 1.1% in the 3rd quarter. Moseley Investment Management Inc. now owns 17,360 shares of the company’s stock valued at $2,704,000 after acquiring an additional 197 shares during the period. Cardinal Capital Management increased its holdings in shares of Johnson & Johnson by 0.9% in the 3rd quarter. Cardinal Capital Management now owns 100,936 shares of the company’s stock valued at $15,721,000 after acquiring an additional 925 shares during the period. First Affirmative Financial Network increased its holdings in shares of Johnson & Johnson by 3.4% in the 3rd quarter. First Affirmative Financial Network now owns 4,803 shares of the company’s stock valued at $748,000 after acquiring an additional 156 shares during the period. City State Bank increased its holdings in shares of Johnson & Johnson by 0.9% in the 3rd quarter. City State Bank now owns 13,320 shares of the company’s stock valued at $2,075,000 after acquiring an additional 118 shares during the period. Finally, Buttonwood Financial Advisors Inc. increased its holdings in shares of Johnson & Johnson by 3.8% in the 3rd quarter. Buttonwood Financial Advisors Inc. now owns 4,154 shares of the company’s stock valued at $647,000 after acquiring an additional 153 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $146.13 on Friday. The stock has a market cap of $352.14 billion, a PE ratio of 9.11, a price-to-earnings-growth ratio of 2.45 and a beta of 0.53. The business has a 50-day simple moving average of $155.26 and a 200-day simple moving average of $155.32. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.38. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $175.97.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a return on equity of 36.43% and a net margin of 45.26%. The firm had revenue of $21.38 billion during the quarter, compared to analyst estimates of $21.39 billion. During the same quarter in the previous year, the business earned $2.68 EPS. Johnson & Johnson’s revenue for the quarter was up 2.3% compared to the same quarter last year. On average, equities analysts expect that Johnson & Johnson will post 10.65 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st will be paid a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.39%. The ex-dividend date of this dividend is Monday, May 20th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s payout ratio is currently 29.68%.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. HSBC upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their price target for the company from $169.00 to $170.00 in a report on Thursday, April 18th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. Raymond James boosted their target price on Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 3rd. Royal Bank of Canada dropped their target price on Johnson & Johnson from $181.00 to $175.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 17th. Finally, Morgan Stanley dropped their target price on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 17th. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $175.86.

Insider Activity at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 59,397 shares of Johnson & Johnson stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the transaction, the executive vice president now owns 141,416 shares in the company, valued at approximately $22,099,078.32. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the sale, the insider now directly owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Jennifer L. Taubert sold 59,397 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the sale, the executive vice president now owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.